Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Jul 1;357(Pt 1):297–303. doi: 10.1042/0264-6021:3570297

Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

M Kortylewski 1, P C Heinrich 1, M E Kauffmann 1, M Böhm 1, A MacKiewicz 1, I Behrmann 1
PMCID: PMC1221955  PMID: 11415463

Abstract

The mitogen-activated protein kinases (MAPKs) extracellular signal-regulated protein kinase (ERK)1 and ERK2, involved in regulating cell growth and differentiation, are constitutively active in A375 and WM239 human melanoma cells. Using PD098059, an inhibitor of MAPK kinase (MEK), we investigated the role of persistently activated ERK1/2 in cell growth. The inhibition of MAPK activity induced a dose-dependent growth arrest in G(0)/G(1) phase. Correspondingly, we observed the up-regulation of the cyclin-dependent kinase (Cdk) inhibitor p27/Kip1 and hypophosphorylation of the retinoblastoma protein. Further studies showed that PD098059 treatment significantly decreased Cdk2 kinase activity, most probably owing to an augmented level of p27/Kip1 associated with cyclin E-Cdk2 complexes. The accumulation of p27/Kip1 protein in A375 cells was attributed to its increased stability. Our findings suggest that constitutively active ERK1/2 kinases contribute to the growth of melanoma cells by negative regulation of the p27/Kip1 inhibitor.

Full Text

The Full Text of this article is available as a PDF (214.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albino A. P., Sozzi G., Nanus D. M., Jhanwar S. C., Houghton A. N. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene. 1992 Nov;7(11):2315–2321. [PubMed] [Google Scholar]
  2. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., Barone M. V., Chiappetta G., Vento M. T., Spiezia S. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest. 1999 Oct;104(7):865–874. doi: 10.1172/JCI6443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ball N. J., Yohn J. J., Morelli J. G., Norris D. A., Golitz L. E., Hoeffler J. P. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994 Mar;102(3):285–290. doi: 10.1111/1523-1747.ep12371783. [DOI] [PubMed] [Google Scholar]
  4. Borner C., Schlagbauer Wadl H., Fellay I., Selzer E., Polterauer P., Jansen B. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 1999 Aug;9(4):347–350. doi: 10.1097/00008390-199908000-00002. [DOI] [PubMed] [Google Scholar]
  5. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999 Jul 29;400(6743):468–472. doi: 10.1038/22788. [DOI] [PubMed] [Google Scholar]
  6. Davies S. P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95–105. doi: 10.1042/0264-6021:3510095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Englaro W., Bertolotto C., Buscà R., Brunet A., Pagès G., Ortonne J. P., Ballotti R. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem. 1998 Apr 17;273(16):9966–9970. doi: 10.1074/jbc.273.16.9966. [DOI] [PubMed] [Google Scholar]
  8. Flørenes V. A., Lu C., Bhattacharya N., Rak J., Sheehan C., Slingerland J. M., Kerbel R. S. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999 Jan 28;18(4):1023–1032. doi: 10.1038/sj.onc.1202382. [DOI] [PubMed] [Google Scholar]
  9. Flørenes V. A., Maelandsmo G. M., Kerbel R. S., Slingerland J. M., Nesland J. M., Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol. 1998 Jul;153(1):305–312. doi: 10.1016/S0002-9440(10)65572-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gemma A., Takenoshita S., Hagiwara K., Okamoto A., Spillare E. A., McMemamin M. G., Hussain S. P., Forrester K., Zariwala M., Xiong Y. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer. 1996 Nov 27;68(5):605–611. doi: 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  11. Harbour J. W., Dean D. C. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol. 2000 Apr;2(4):E65–E67. doi: 10.1038/35008695. [DOI] [PubMed] [Google Scholar]
  12. Henriet P., Zhong Z. D., Brooks P. C., Weinberg K. I., DeClerck Y. A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10026–10031. doi: 10.1073/pnas.170290997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hermeking H., Funk J. O., Reichert M., Ellwart J. W., Eick D. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 1995 Oct 5;11(7):1409–1415. [PubMed] [Google Scholar]
  14. Jafari M., Papp T., Kirchner S., Diener U., Henschler D., Burg G., Schiffmann D. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol. 1995;121(1):23–30. doi: 10.1007/BF01202725. [DOI] [PubMed] [Google Scholar]
  15. Jansen B., Schlagbauer-Wadl H., Kahr H., Heere-Ress E., Mayer B. X., Eichler H., Pehamberger H., Gana-Weisz M., Ben-David E., Kloog Y. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14019–14024. doi: 10.1073/pnas.96.24.14019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kerkhoff E., Rapp U. R. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol. 1997 May;17(5):2576–2586. doi: 10.1128/mcb.17.5.2576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kortylewski M., Heinrich P. C., Mackiewicz A., Schniertshauer U., Klingmüller U., Nakajima K., Hirano T., Horn F., Behrmann I. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999 Jun 24;18(25):3742–3753. doi: 10.1038/sj.onc.1202708. [DOI] [PubMed] [Google Scholar]
  18. Lloyd A. C. Ras versus cyclin-dependent kinase inhibitors. Curr Opin Genet Dev. 1998 Feb;8(1):43–48. doi: 10.1016/s0959-437x(98)80060-9. [DOI] [PubMed] [Google Scholar]
  19. Lloyd R. V., Erickson L. A., Jin L., Kulig E., Qian X., Cheville J. C., Scheithauer B. W. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999 Feb;154(2):313–323. doi: 10.1016/S0002-9440(10)65277-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mansour S. J., Matten W. T., Hermann A. S., Candia J. M., Rong S., Fukasawa K., Vande Woude G. F., Ahn N. G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994 Aug 12;265(5174):966–970. doi: 10.1126/science.8052857. [DOI] [PubMed] [Google Scholar]
  21. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massagué J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994 Jul 15;78(1):59–66. doi: 10.1016/0092-8674(94)90572-x. [DOI] [PubMed] [Google Scholar]
  22. Ravi R. K., Weber E., McMahon M., Williams J. R., Baylin S., Mal A., Harter M. L., Dillehay L. E., Claudio P. P., Giordano A. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest. 1998 Jan 1;101(1):153–159. doi: 10.1172/JCI831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999 Jun 15;13(12):1501–1512. doi: 10.1101/gad.13.12.1501. [DOI] [PubMed] [Google Scholar]
  24. Su B., Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 1996 Jun;8(3):402–411. doi: 10.1016/s0952-7915(96)80131-2. [DOI] [PubMed] [Google Scholar]
  25. Takuwa N., Takuwa Y. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol. 1997 Sep;17(9):5348–5358. doi: 10.1128/mcb.17.9.5348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yasuda H., Kobayashi H., Ohkawara A., Kuzumaki N. Differential expression of ras oncogene products among the types of human melanomas and melanocytic nevi. J Invest Dermatol. 1989 Jul;93(1):54–59. doi: 10.1111/1523-1747.ep12277350. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES